Wellness peptide craze: Why people are injecting drugs not for human consumption - BBC

Summary

In response to the explosion of the unregulated peptides market, the MHRA, the body responsible for licensing and overseeing the use of medicines in the UK, says that it does not accept attempts to evade medicines regulation by selling peptides for research purposes where evidence indicates they…

Source: BBC

(0)

AI News Q&A (Free Content)

This content is freely available. No login required. Disclaimer: Following content is AI generated from various sources including those identified below. Always check for accuracy. No content here is an advice. Please use the contact button to share feedback about any inaccurate content generated by AI. We sincerely appreciate your help in this regard.

Q1: What are the regulatory challenges associated with the sale of peptides in the UK?

A1: The sale of peptides in the UK faces significant regulatory challenges due to their classification in a 'grey area' under the Medicines and Healthcare products Regulatory Agency (MHRA). Peptides marketed for 'research purposes only' are not strictly regulated as medicines. However, if marketed or used implying therapeutic application, the MHRA can take action. This creates uncertainty for companies, especially post-Brexit, as UK regulations have diverged from EU rules. Personal possession of research peptides is not criminalized, but commercial sale without a license is illegal.

Q2: How is the use of peptides for wellness and anti-aging treatments viewed under UK regulations?

A2: In the UK, the use of peptides for wellness and anti-aging treatments is largely unregulated. Peptides like Retatrutide and MOTS-C are often marketed under the guise of 'wellness' or 'regenerative' therapy without MHRA approval. The 'research only' label does not offer legal immunity if the context suggests therapeutic use. Misuse can lead to regulatory non-compliance and risk professional licenses, as the MHRA requires that any therapeutic claims must be supported by regulatory compliance.

Q3: What are the potential health effects of peptides used in treatments according to recent scientific research?

A3: Recent scientific research highlights that peptides, like those mimicking glucagon-like peptide-1 (GLP-1), can have significant health effects, such as improving insulin sensitivity and glucose homeostasis. However, they can also cause adverse effects like nausea and abdominal pain. A study on Polygonatum cyrtonema polysaccharides, which interact with GLP-1, showed they could reduce fasting blood glucose and improve metabolic disorders, indicating potential for safer alternatives to synthetic peptides.

Q4: What legal framework governs the regulation of peptides in the UK?

A4: The legal framework for peptides in the UK is governed by the Medicines Act 1968, allowing the MHRA to classify substances based on potential harm and intended use. Peptides are often classified as prescription-only medicines (POMs) or are unregulated if sold for research purposes. However, the MHRA can intervene if these are marketed as having therapeutic uses without authorization. This framework aims to ensure safety, quality, and efficacy of medicines.

Q5: How does the UK peptide market compare post-Brexit in terms of regulation and enforcement?

A5: Post-Brexit, the UK's peptide market operates under its own regulatory framework, distinct from the EU. This has led to increased regulatory uncertainties and enforcement challenges, particularly regarding imports and compliance with Good Manufacturing Practice (GMP) standards. The MHRA focuses on unlicensed sales and trafficking of controlled substances, with recent actions including large seizures of unlicensed weight loss peptides, emphasizing the need for regulatory adherence.

Q6: What role do natural polysaccharides play as an alternative to synthetic peptides in diabetes treatment?

A6: Natural polysaccharides, like those from Polygonatum cyrtonema, are emerging as promising alternatives to synthetic peptides for diabetes treatment. Recent studies show that these polysaccharides can significantly reduce fasting blood glucose and improve insulin sensitivity by modulating gut microbiota and promoting short-chain fatty acid production. They offer a safer profile compared to conventional hypoglycemic agents, which can impair gastrointestinal function.

Q7: What are the implications of labeling peptides as 'research only' in terms of legal compliance and marketing?

A7: Labeling peptides as 'research only' implies they are for in vitro use and not for human consumption. However, this does not provide legal immunity if marketed in a way suggesting therapeutic use. The MHRA requires that any health benefits or therapeutic claims be backed by proper medicinal licenses. Unauthorized marketing can lead to regulatory actions and pose risks to those involved in their sale or distribution.

References:

Processing-induced structural remodeling enhances the hypoglycemic activity of Polygonatum cyrtonema Hua polysaccharides via gut microbiota-SCFA-GPR41/43 pathway.